Intensity Therapeutics(US:INTS) Prnewswire·2025-12-04 12:47Core Insights - Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company focused on developing proprietary cancer therapies using non-covalent drug-conjugation technology aimed at killing tumors and enhancing immune system recognition of cancers [1][4] Presentations - The company will present two studies at the 2025 San Antonio Breast Cancer Symposium, including a focus on a new drug offering safer breast cancer therapy combinations and early observations from a Phase II randomized clinical trial involving intratumoral injections of INT230-6 [2][3] Product Overview - INT230-6 is the lead investigational product candidate designed for direct intratumoral injection, combining cisplatin and vinblastine sulfate with a diffusion enhancer to improve drug dispersion within tumors, leading to effective tumor killing and immune engagement without immunosuppression [3][4] Clinical Trials - Intensity has completed two clinical studies with over 200 patients using INT230-6, including a Phase 1/2 study in metastatic cancers and a Phase 2 randomized control trial in locally advanced breast cancer, with ongoing trials evaluating INT230-6 in soft tissue sarcoma and presurgical triple-negative breast cancer [4][5]